Chemed Corporation $CHE Shares Sold by EULAV Asset Management

EULAV Asset Management lowered its stake in Chemed Corporation (NYSE:CHE) by 22.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 95,205 shares of the company’s stock after selling 28,313 shares during the period. EULAV Asset Management’s holdings in Chemed were worth $42,627,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Creekmur Asset Management LLC acquired a new position in shares of Chemed in the 2nd quarter valued at $28,000. First Horizon Corp acquired a new stake in Chemed during the 3rd quarter worth about $31,000. Parkside Financial Bank & Trust lifted its position in Chemed by 86.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock worth $46,000 after acquiring an additional 44 shares during the period. HM Payson & Co. grew its stake in Chemed by 35.5% during the 3rd quarter. HM Payson & Co. now owns 103 shares of the company’s stock valued at $46,000 after purchasing an additional 27 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares during the period. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Chemed Stock Up 1.5%

Chemed stock opened at $458.70 on Friday. The business’s 50-day moving average price is $435.31 and its 200 day moving average price is $444.55. The firm has a market cap of $6.50 billion, a price-to-earnings ratio of 24.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.44. Chemed Corporation has a 52 week low of $408.42 and a 52 week high of $623.60.

Chemed (NYSE:CHE) last released its quarterly earnings data on Tuesday, October 28th. The company reported $5.27 EPS for the quarter, missing the consensus estimate of $5.39 by ($0.12). The company had revenue of $624.90 million during the quarter, compared to analysts’ expectations of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.The company’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Equities analysts expect that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Monday, November 17th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.5%. The ex-dividend date was Monday, November 17th. Chemed’s dividend payout ratio (DPR) is currently 12.69%.

Insiders Place Their Bets

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $437.55, for a total value of $875,100.00. Following the completion of the transaction, the chief executive officer owned 94,197 shares in the company, valued at approximately $41,215,897.35. This represents a 2.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 30th. Royal Bank Of Canada reduced their price target on shares of Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a research report on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $574.25.

Chemed Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.